Ascentage Pharma Group International 2023 Sustainability Report
Company: Ascentage Pharma Group International
Sector: Manufacturing
Country: China
Year: 2023
Type: Sustainability Report
Pages: 88
The report describes a year of continued R&D investment and innovation, including RMB707 million of annual R&D investment and progress across the Company's drug pipeline. It reports 7,776.66 tCO2e of combined Scope 1 and Scope 2 emissions in 2023 and sets longer-term environmental objectives, including a 50% reduction in carbon emissions from peak levels by 2040. The company had 586 full-time employees at the reporting-period end and reported zero work-related fatalities. ESG oversight is assigned to the Board of Directors as the highest responsible body, with the Audit Committee supervising ESG work.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.